Under 10% of people that would benefit from weight-loss injections including Wegovy have access to them, states the World Health Organization as it releases its first guidance on the medications.
Considering over a billion individuals worldwide currently living with obesity, it is urging increased and just access to these injectable treatments.
According to estimates, more than two billion will be obese by 2030 without intervention.
"The latest guidance recognises that excess weight is a chronic disease that can be managed with thorough and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are major barriers to universal access to the injections that can help people shift considerable weight, notes the body.
Skinny Jab Shortage
Even in the present most favorable scenario, the manufacturing of such drugs might only reach approximately 100 million people – fewer than 10% of eligible patients, according to the health organization.
The advice encourages nations and manufacturers to widen access, through measures including patent sharing.
Exclusive production rights on a key compound – the core component of the drug Wegovy – is set to lapse in multiple nations in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs replicate a body's own hormone to slow digestion, curb appetite and increase satiety so individuals reduce food intake.
Patients commonly begin shedding pounds after several weeks of commencing the weekly injections.
Research indicates users may see weight return after a year of halting the drug, when their usual food cravings return.
To be carrying excess weight raises your likelihood for experiencing medical conditions, such as type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight impacts individuals in countries worldwide and was responsible for millions of deaths worldwide in 2024, per the health agency.
